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NPC1L1 and Risk of
Gallstone DiseaseWe read with great interest the recent paper by Ference
et al. (1) using genetic variants in NPC1L1 (target for
ezetimibe) and HMGCR (target for statins) to predict the
effect of ezetimibe and statins on low-density
lipoprotein (LDL) cholesterol and risk of coronary heart
disease. Ezetimibe reduces plasma levels of LDL
cholesterol by inhibiting Niemann-Pick C1-like protein
1 (NPC1L1), a transporter responsible for cholesterol
uptake from the intestine into enterocytes and from bile
into hepatocytes in humans. In a recent study of
67,385 individuals from the general population (2), we
genotyped 4 common NPC1L1 variants, previously
associated with reduced LDL cholesterol levels, and
calculated a weighted genotype score. LDL cholesterol
decreased stepwise up to 3.5%, and risk of ischemic
vascular disease decreased up to 18% in those with the
highest versus lowest genotype scores. These ﬁndings
are in agreement with results from Ference et al. (1), and
a recent study on rare loss-of-function variants in
NPC1L1 (3). However, in our study, genotype score also
associated with a 22% increase in risk of symptomatic
gallstone disease. This is biologically plausible, because
in humans where NPC1L1 is expressed both in the
intestine and in the liver, inhibition of hepatic NPC1L1 is
likely to increase biliary cholesterol and the propensity
for gallstone formation. This raises the clinically relevant
question whether long-term treatment with ezetimibe
might increase the risk of gallstones. According to the
product insert of Zetia (Merck, Kenilworth, New Jersey),
treatment of dogs (which express hepatic NPC1L1) with
high doses of ezetimibe for a month increased biliary
cholesterol 2- to 4-fold (4), suggesting that a long-term,
on-target effect of ezetimibe monotherapy might be an
increased risk of gallstones. That said, it is reassuring
that 6 years of treatment with ezetimibe in combination
with a statin did not seem to increase the risk of
gallstones (5).Bo Kobberø Lauridsen, MD
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and Risk of Gallstone DiseaseDr. Lauridsen and colleagues raise the biologically plau-
siblehypothesis that inhibiting cholesterol absorption from
bile during treatmentwith ezetimibemay increase the risk
for symptomatic gallbladder disease (GBD). They report
that persons with a greater number of polymorphisms in
the NPC1L1 gene (target of ezetimibe) had lower low-
density lipoprotein cholesterol (LDL-C), a lower risk of
coronary heart disease, and a greater risk of GBD
(relative risk [RR]: 1.07; 95% conﬁdence interval [CI]:
1.02 to 1.15; p ¼ 0.02, comparing persons with scores
above and below 5) (1). On closer inspection of these
data, however, the effect of Niemann-Pick C1-like
protein 1 (NPC1L1) polymorphisms on the risk of GBD
appears to be limited to women in Copenhagen (women:
RR: 1.10; 95% CI: 1.03 to 1.19; p ¼ 0.01; men: RR: 1.00;
95%CI: 0.89 to 1.12; p¼ 0.83).
We therefore evaluated the effect of NPC1L1 poly-
morphisms on the risk of GBD among women in our
data (2). We did not ﬁnd any association between
NPC1L1 polymorphisms and the risk of GBD, either
alone or when combined with polymorphisms in the
gene that encodes the target of statins (RR: 1.02;
95% CI: 0.97 to 1.08; p ¼ 0.49, comparing persons
with NPC1L1 scores above and below median). Our
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1087results agree with a recent genome-wide association
study of GBD among women that reported that the
NPC1L1 rs2072183 polymorphism was not associated
with GBD (p ¼ 0.39) (3). When data from all 3
studies are combined, lower LDL-C mediated by
polymorphisms in NPC1L1 does not appear to be
associated with a signiﬁcantly increased risk of GBD
(Figure 1). This result agrees closely with the lack of
association between treatment with ezetimibe and
the risk of GBD over a mean of 6-years follow-up in
the IMPROVE-IT (Examining Outcomes in Subjects
With Acute Coronary Syndrome: Vytorin [Ezetimibe/
Simvastatin] Versus Simvastatin [P04103]) trial (4).
By contrast, increased cholesterol secretion into bile
mediated polymorphisms in the ABCG5/G8 gene was
robustly associated with an increased risk of GBD in all
3 studies (Figure 1). As compared to polymorphisms in
NPC1L1, lower LDL-C–mediated polymorphisms in
ABCG5/G8 were associated with a 10-fold greaterincreased risk of GBD per unit change in LDL-C and
several orders of magnitude greater statistical
evidence for a causal effect (p ¼ 3.1  10-187 vs.
p ¼ 0.06). It would appear therefore that the culprit
for increased risk of GBD is increased cholesterol
secretion into bile rather than decreased cholesterol
absorption. As a result, even if LDL-C has a cumulative
effect on GBD, as it appears to have on coronary heart
disease (5), the combined genetic data and the results
of IMPROVE-IT suggest that symptomatic GBD is
unlikely to be a signiﬁcant on-target treatment effect
of ezetimibe, even if treatment is long term.*Brian A. Ference, MD, MPhil, MSc
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2012;60:2631–9.Duration of Triple Therapy
in Patients Requiring
Oral Anticoagulation After
Drug-Eluting
Stent ImplantationTABLE 1 Stent Types Used in the ISAR-TRIPLE Trial
6 Weeks of
Therapy
(n ¼ 417)
6 Months
of Therapy
(n ¼ 409)
First-generation DES (SES, PES) 29 (6) 16 (4)
Second-generation DES (EES, ZES) 203 (49) 206 (50)
BA-DES, BD-DES, DES-Ab, DEB 183 (44) 186 (45)
Values are n (%).
BA-DES ¼ bioabsorbable-drug eluting stent(s); BD-DES ¼ biodegradable
drug-eluting stent(s); DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent(s);
DES-Ab ¼ Abluminal biodegradable polymer metallic drug-eluting stent(s); EES ¼
everolimus-eluting stent(s); ISAR-TRIPLE ¼ Duration of Triple Therapy in Patients
Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation; PES ¼
paclitaxel-eluting stent(s); SES ¼ sirolimus-eluting stent(s); ZES ¼ zotarolimus-
eluting stent(s).We read with much interest the paper and editorial by
Fiedler et al. (1) and Bhatt et al. (2) regarding the
optimal duration of dual antiplatelet therapy (DAPT)
in patients on systemic anticoagulation in a recent
issue of the Journal. In this randomized, open-label
trial, 614 patients underwent drug-eluting stent
(DES) implantation and were randomized to either
6 weeks or 6 months of clopidogrel therapy. They
found no difference in the primary endpoint
(composite of death, myocardial infarction, deﬁnite
stent thrombosis, stroke, or TIMI [Thrombolysis In
Myocardial Infarction] major bleeding) between
the 2 groups (9.8% vs. 8.8%; p ¼ 0.63). In addition,
the secondary combined ischemic endpoint of
cardiac death, myocardial infarction, deﬁnite stent
thrombosis, and ischemic stroke was no different
(4.0% vs. 4.3%; p ¼ 0.87), and there was also no
difference in the TIMI major bleeding between the
groups.Despite the important ﬁndings of this study,
some concerns remain unanswered that may limit the
broader clinical application of the results of this
study. The investigators used a large number of stent
types in this study including ﬁrst-generation, second-
generation, and newer-generation (bioabsorbable/
degradable) DES (Table 1). In summary, $44% of the
stents implanted in the study included newer-
generation DES (bioabsorbable/biodegradable stents).
These could potentially affect the efﬁcacy and safety
of this strategy when applied to a larger unrestricted
population.
There was an increased risk of stent thrombosis
with ﬁrst-generation DES that led to the development
of DES with biocompatible polymers and more re-
cently biodegradable polymers and bioabsorbable
vascular scaffolds. We have shown compelling data
for safety and efﬁcacy of second-generation DES
with biocompatible polymers in a large spectrum
of patients including those at high risk for stent
thrombosis (3). The newer DES with bioabsorbable/
biodegradable polymers and stents that allow for
complete dissolution of polymer or bioscaffold
leaving either a residual metal platform or native
vessel would, in theory, reduce the rates of stent
thrombosis. Biodegradable polymer biolimus-eluting
stents were perceived to be safer than ﬁrst-
generation sirolimus-eluting stents on the basis of
the results of individual trials that were powered for
only composite endpoints of safety and efﬁcacy.
However, in the largest mixed comparison meta-
analysis of >61 trials involving 63,242 patients, there
was a signiﬁcant increase in the odds of myocardial
infarction (1.29; 95% conﬁdence interval: 1.02 to 1.69)
with the use of biodegradable polymer DES versus
the second-generation DES at 1 year (4). In fact, the
second-generation DES was associated with the most
favorable safety proﬁle. Additionally, another mixed
comparison meta-analysis that included 77 studies
